Skip to main content
Daniel Troy, MD, Orthopaedic Surgery, Oak Lawn, IL

Daniel Anthony Troy MD

Orthopedic Spine Surgery, Orthopedic Sports Medicine


Physician

Join to View Full Profile
  • 6701 W 95th StOak Lawn, IL 60453

  • Phone+1 708-599-5000

  • Fax+1 708-599-5000

Are you Dr. Troy?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Daniel Troy, MD is a board certified orthopedic surgeon in Oak Lawn, Illinois. He is currently licensed to practice medicine in Illinois, Kentucky, and Alabama.

Education & Training

  • University of Illinois College of Medicine at Chicago
    University of Illinois College of Medicine at ChicagoResidency, Orthopaedic Surgery, 1995 - 2000
  • Rush Medical College of Rush University Medical Center
    Rush Medical College of Rush University Medical CenterClass of 1995

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1995 - 2026
  • IL State Medical License
    IL State Medical License 1997 - 2026
  • KY State Medical License
    KY State Medical License 2002 - 2004
  • AL State Medical License
    AL State Medical License 2000 - 2001
  • GA State Medical License
    GA State Medical License 2000 - 2001
  • Orthopaedic Surgery
    American Board of Orthopaedic Surgery Orthopaedic Surgery
  • Orthopaedic Sports Medicine
    American Board of Orthopaedic Surgery Orthopaedic Sports Medicine

Press Mentions

  • Neurorx, Inc. And Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business Combination
    Neurorx, Inc. And Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business CombinationMarch 15th, 2021
  • NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI Health
    NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI™ for Severe COVID-19 with UCI HealthFebruary 3rd, 2021
  • CORRECTION: NeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (Aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU Patients
    CORRECTION: NeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (Aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU PatientsNovember 25th, 2020
  • Join now to see all